Emerging drugs for Guillain-Barré syndrome

@article{Walgaard2011EmergingDF,
  title={Emerging drugs for Guillain-Barr{\'e} syndrome},
  author={Christa Walgaard and Bart C. Jacobs and Pieter A. van Doorn},
  journal={Expert Opinion on Emerging Drugs},
  year={2011},
  volume={16},
  pages={105 - 120}
}
Introduction: Intravenous immunoglobulin (IVIg) and plasma exchange are proven effective treatments for Guillain-Barré syndrome (GBS). However, this treatment is insufficient for many patients as 1 – 5% die, 25% need artificial respiration, 20% are still unable to walk unaided after 6 months and 85% have residual symptoms, such as fatigue and pain. Areas covered: Strategies to design and conduct trials with new compounds and individualized regimens of IVIg are discussed. The development of… 
The immunotherapy of Guillain-Barré syndrome
TLDR
This review offers a comprehensive view of the current treatment based upon the physiopathology of Guillain-Barré syndrome, finding new biomarkers and establishing algorithms of prediction of both the disease and its outcomes is warranted.
Immunotherapy of Guillain-Barré syndrome
TLDR
Good circumstantial evidence exists for a pathogenic role for molecular mimicry in GBS pathogenesis, especially with its axonal forms, providing insights that could guide future immunotherapy, and the potential of leukocyte trafficking inhibitors as novel disease-specific immunotherapeutic drugs is highlighted.
Assessment of New Strategies in the Management of Guillain Barre Syndrome: Cairo University
TLDR
The combination of IVIG and intravenous steroid can be used to hasten recovery in moderate GBS and the use of 10 sessions of PE can decrease the need for mechanical ventilation.
Guillain-Barré Syndrome: What We Know and Where We Can Improve
Guillain-Barre Syndrome (GBS) is a neurological syndrome inwhich the axon andmyelin sheaths of the peripheral nervous system are attacked by the immune system. GBS is characterised by its rapid onset
Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barré syndrome
TLDR
A meaningful difference is revealed for the MV weaning and precocious recovery in IvIg group compared to PE group for GBS adults with GBS in intensive care unit.
[2011: What's new in dysimmune neuropathies].
TLDR
The exploration of novel therapeutic approaches including monoclonal antibodies and oral immunosuppressants, known from multiple sclerosis studies, suggests new approaches to treatment.
Guillain-Barré syndrome.
TLDR
There are now well-documented acute "monophasic" polyneuropathies that have a different clinical phenomenology than that described originally by Guillain, Barré, and Strohl: Miller Fisher syndrome, pure sensory neuropathy/neuronopathy, pandysautonomia, and oropharyngeal variant.
Successful Treatment of Refractory Guillain-Barré Syndrome with Alemtuzumab in a Patient with Chronic Lymphocytic Leukemia
TLDR
His clinical and neurologic condition continued to deteriorate despite sequential treatment with corticosteroids, intravenous immunoglobulin and plasmapheresis, but in the end, he had a complete and durable response to treatment with alemtuzumab.
Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach
TLDR
Development of anti-ganglioside antagonists can serve as targeted therapy for the treatment of GBS and will open a new approach of drug development with maximum efficacy and specificity.
Recent developments and future directions in Guillain‐Barré syndrome
TLDR
An overview and critical assessment of the most recent developments and future directions in GBS research are provided.
...
1
2
3
...

References

SHOWING 1-10 OF 131 REFERENCES
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
TLDR
Advances in prognostic modelling have resulted in the development of a new and simple prognostic outcome scale that might also help to guide new treatment options, particularly in patients with GBS who have a poor prognosis.
Treatment of Guillain–Barré syndrome with mycophenolate mofetil: a pilot study
TLDR
An open label pilot study to assess the additional effect of MM, administered simultaneously with IVIg and MP, in patients with GBS and whether there is a tendency to improved outcome.
Immunotherapy for Guillain-Barré syndrome: a systematic review.
TLDR
Limited evidence from three open trials in children suggested that IVIg hastens recovery compared with supportive care alone, and more research is needed to identify better treatment regimens and new therapeutic strategies.
Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome
TLDR
In treatment of severe Guillain-Barré syndrome during the first 2 weeks after onset of neuropathic symptoms, PE and IVIg had equivalent efficacy and the combination of PE withIVIg did not confer a significant advantage.
Intravenous immunoglobulin for Guillain-Barré syndrome.
TLDR
Moderate quality evidence is provided that, in severe disease, IVIg started within two weeks from onset hastens recovery as much as PE, but more research is needed in mild disease and in patients whose treatment starts more than two weeks after onset.
Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré Syndrome Steroid Trial Group.
  • Medicine
    Lancet
  • 1993
TLDR
A short course of high-dose IVMP given early in GBS is ineffective, and there was no significant difference in any outcome variable between patients treated with IVMP and those given placebo.
Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barré Syndrome: A Randomized Trial
TLDR
Treatment with IVIG before loss of unaided walking did not give rise to a less severe course, but recovery occurred somewhat faster, and multivariate analysis with Cox regression showed that disease severity at the nadir was the only prognostic factor for recovery.
Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome
TLDR
The diagnosis of acute-onset chronic inflammatory demyelinating polyneuropathy (CIDP) should be considered when a patient thought to have Guillain-Barré syndrome deteriorates again after 8 weeks from onset or when deterioration occurs 3 times or more.
Prominent Plasmacytosis Following Intravenous Immunoglobulin Correlates with Clinical Improvement in Guillain-Barré Syndrome
TLDR
A strong negative correlation between the absolute number of IVIg-mobilized plasma cells and time to improve neurological function in both retrospective and prospective studies of Guillain-Barré syndrome (GBS).
...
1
2
3
4
5
...